BCL2L12 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Jurkat T lymphoblastoid line, with targeted disruption of the BCL2L12 gene. This loss-of-function model provides a heterogeneous pool of cells lacking BCL2L12 expression, avoiding clonal selection and enabling population-level analyses. The product is delivered as a suspension culture, ready for functional assays in apoptosis and signaling research.
The Jurkat line is a CD4+ T lymphoblastoid cell model widely used for studying T cell activation and apoptosis. Established from a patient with acute T cell leukemia, Jurkat cells exhibit p53 proficiency and intact DNA damage responses, making them a prime system for investigating genotoxic stress-induced cell death. Their suspension growth and well-characterized apoptotic pathways support scalable experimental workflows, from mechanistic studies to drug screening.
BCL2L12 encodes a pro-apoptotic BH3-only protein that functions in the intrinsic apoptosis pathway. Transcriptionally upregulated by p53 and E2F1 via ATM/ATR signaling upon DNA damage, BCL2L12 protein then binds and neutralizes anti-apoptotic BCL2 family members including BCL2, BCL-XL, and MCL1. This facilitates BAX and BAK oligomerization, mitochondrial outer membrane permeabilization, cytochrome c release, and subsequent activation of the caspase-9/caspase-3 cascade. Thus, BCL2L12 acts as a stress-responsive apoptotic switch linking upstream damage sensors to the core executioner machinery.
In Jurkat cells, BCL2L12 knockout removes a critical pro-apoptotic signal, likely rendering the cells resistant to a range of death stimuli such as chemotherapeutics and p53-activating agents. By freeing anti-apoptotic BCL2 proteins to inhibit BAX/BAK-mediated mitochondrial permeabilization, the loss shifts the balance toward survival. This phenotype mirrors resistance mechanisms in T-cell acute lymphoblastic leukemia, where diminished BH3-only protein function promotes tumor cell survival, making the model valuable for studying therapy failure and apoptosis evasion.
Key applications include dissecting p53-mediated apoptosis, evaluating BH3 mimetics, and screening for compounds that can override BCL2L12 deficiency. Standard assays such as caspase-3/PARP Western blot, Annexin V/PI flow cytometry, and mitochondrial membrane potential measurements (JC-1/TMRM) are directly applicable. Co-immunoprecipitation enables mapping of BCL2 family interactions, while qRT-PCR validates knockout maintenance. Population-level analysis facilitates robust drug-response profiling and genetic interaction studies. For further information, please contact Ascent Research.
